Romy Kerber, Eva Lorenz, Sophie Duraffour, Daouda Sissoko, Martin Rudolf, Anna Jaeger, Sekou Ditinn Cisse, Alseny-Modet Camara, Osvaldo Miranda, Carlos M Castro, Joseph Akoi Bore, Fara Raymond Koundouno, Johanna Repits, Babak Afrough, Beate Becker-Ziaja, Julia Hinzmann, Marc Mertens, Ines Vitoriano, Christopher Hugh Logue, Jan-Peter Böttcher, Elisa Pallasch, Andreas Sachse, Amadou Bah, Mar Cabeza-Cabrerizo, Katja Nitzsche, Eeva Kuisma, Janine Michel, Tobias Holm, Elsa Gayle Zekeng, Lauren A Cowley, Isabel Garcia-Dorival, Nicole Hetzelt, Jonathan Hans Josef Baum, Jasmine Portmann, Lisa Carter, Rahel Lemma Yenamaberhan, Alvaro Camino, Theresa Enkirch, Katrin Singethan, Sarah Meisel, Antonio Mazzarelli, Abigail Kosgei, Liana Kafetzopoulou, Natasha Y Rickett, Livia Victoria Patrono, Luam Ghebreghiorghis, Ulrike Arnold, Géraldine Colin, Sylvain Juchet, Claire Levy Marchal, Jacques Seraphin Kolie, Abdoul Habib Beavogui, Stephanie Wurr, Sabrina Bockholt, Ralf Krumkamp, Jürgen May, Kilian Stoecker, Erna Fleischmann, Giuseppe Ippolito, Miles W Carroll, Lamine Koivogui, N'Faly Magassouba, Sakoba Keita, Céline Gurry, Patrick Drury, Boubacar Diallo, Pierre Formenty, Roman Wölfel, Antonino Di Caro, Martin Gabriel, Xavier Anglaret, Denis Malvy, Stephan Günther
BACKGROUND: In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients. The cycle threshold (Ct) of an Ebola virus-specific reverse transcription-polymerase chain reaction assay and 13 blood chemistry parameters were measured on admission and during hospitalization. Favipiravir treatment was offered to patients with EVD on a compassionate-use basis. METHODS: To reduce biases in the raw field data, we carefully selected 163 of 286 patients with EVD for a retrospective study to assess associations between potential risk factors, alterations in blood chemistry findings, favipiravir treatment, and outcome...
June 19, 2019: Journal of Infectious Diseases